A five-year prospective study of fatigue in primary Sjögren's syndrome

Abstract

IntroductionFatigue is prevalent in primary Sjögren's syndrome (pSS), and contributes to the considerably reduced health related quality of life in this disease. The symptom is included in proposed disease activity and outcome measures for pSS. Several studies indicate that there is an inflammatory component of fatigue in pSS and other chronic inflammatory rheumatic diseases. The purpose of this study was to investigate fatigue change in pSS in a longitudinal study, and explore whether any clinical or laboratory variables at baseline, including serum cytokines, were associated with a change in fatigue scores over time.MethodsA clinical and laboratory investigation of 141 patients fulfilling the American-European consensus criteria of pSS was undertaken in the period May 2004 to April 2005. Median time since diagnosis was 5.5 years. Examinations included the fatigue questionnaires: fatigue severity scale (FSS), fatigue visual analogue scale (VAS), functional assessment of chronic illness therapy - fatigue (FACIT-F) and medical outcome study short form-36 (SF-36) vitality, which were repeated in a follow-up investigation in January and February 2010.ResultsA total of 122 patients (87%) responded at both time-points. Thirty-five percent of patients experienced a clinically significant FSS increase. On the group level, fatigue measures did not change except that there was a slight deterioration in SF-36 vitality score. High serum anti-Sjögren's syndrome A antigen (anti-SSA) showed weak associations with high baseline fatigue, and patients with increasing fatigue had lower baseline unstimulated whole salivary volume. Weak associations between increasing fatigue and serum immunoglobulin G (IgG), and the pro-inflammatory cytokine interleukin-17 (IL-17), were observed. Baseline sicca symptoms correlated with higher fatigue both at baseline and with increasing fatigue over time. Linear regression analysis did not identify any predictive ability of clinical or laboratory measures on fatigue change over time.ConclusionsFatigue remained mainly unchanged over time. Using multivariate models did not reveal any clinical or laboratory predictors of fatigue change over time.

Fatigue, anxiety and depression overrule the role of oncological treatment in predicting self-reported health complaints in women with breast cancer compared to healthy controls

“…Fatigue Visual Analog Scale (Fatigue-VAS) is a 100 mm line where the far left is 0 ¼ "no problems with fatigue and exhaustion", and the far right is 10 ¼ "so much fatigue and exhaustion that is possible to experience", during the last week [23]. The scale examines the intensity of fatigue reported by the patients during the clinical investigation.…”

Fatigue in Newly Diagnosed Inflammatory Bowel Disease

“…The severity and prevalence of fatigue in newly diagnosed IBD is comparable to that of primary Sjøgren's syndrome and rheumatoid arthritis, and considerably more effort has been put into exploring these issues. 21,22 A higher prevalence of fatigue in IBD patients compared with healthy individuals has previously been reported, 10 but the use of fatigue as a primary outcome has not been widely investigated. This is the first report of fatigue in an IBD cohort consisting of only newly diagnosed patients not receiving anti-inflammatory or immune-modulating medication.…”

Epidemiology of Sjögren’s Syndrome—from an Oral Perspective

“…Patients with SS experience immune-mediated destruction of salivary and lacrimal glands leading to reduced lacrimal and salivary flow. Dry eyes and dry mouth together with fatigue are among the most common complaints [1, 2]. Extraglandular manifestations, such as involvement of the peripheral nervous, pulmonary, or gastrointestinal system, kidney, skin, myalgias, and arthralgias are frequently seen leading to reduced quality of life [3].…”